This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RVNCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
by Zacks Equity Research
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FLGTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Clene (CLNN) points to a 976.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CLNNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 25.26% Upside in Esquire Financial (ESQ): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Esquire Financial (ESQ) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ESQPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Air Transport Services (ATSG) Could Surge 28.87%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Air Transport Services (ATSG) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ATSGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Estee Lauder (EL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Estee Lauder (EL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ELPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
ZIM Integrated Shipping Services (ZIM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ZIM (ZIM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZIMNegative Net Change TRMDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Palo Alto Networks (PANW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Palo Alto (PANW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PANWPositive Net Change STNEPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does RingCentral (RNG) Have the Potential to Rally 25.6% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in RingCentral (RNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RNGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
RXSTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 30.79% Upside in UGI (UGI): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 30.8% upside potential for UGI (UGI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
UGIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does AFC Gamma (AFCG) Have the Potential to Rally 56.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in AFC Gamma (AFCG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AFCGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can a.k.a. Brands (AKA) Climb 33.93% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for a.k.a. Brands (AKA) points to a 33.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AKANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Private Bancorp of America (PBAM) Could Rally 36.44%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Private Bancorp of America (PBAM) points to a 36.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PBAMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Nomad Foods (NOMD) Could Surge 27.25%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Nomad Foods (NOMD) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NOMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
QTTBPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe TransAlta (TAC) Could Rally 62.98%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63% in TransAlta (TAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TACPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 40.9% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BGNENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Flowers Foods (FLO) Reports Next Week: What to Expect
by Zacks Equity Research
Flowers Foods (FLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLOPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OCULPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 55.07% Upside in SoundThinking (SSTI): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 55.1% upside potential for SoundThinking (SSTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SSTIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 53.85% Upside in SunOpta (STKL): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 53.9% upside potential for SunOpta (STKL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
STKLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SUPNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRBPPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BCYCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate